Dermatology and therapy · 2026
Patient Satisfaction Using Guselkumab Self-administered Using the One-Press Device for Treatment of Moderate-to-Severe Psoriasis: Results from a National, Prospective, Real-World Study in Portugal (CERES Study).
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Torres Tiago, Sousa João Teles, Antunes Joana, Mendes-Bastos Pedro, Brasileiro Ana, Neto Vítor, Henrique Martinha, Pimenta Rita, Magina Sofia, Lourenço Diana, Mota Fernando
Аннотация
INTRODUCTION: Guselkumab, a selective p19 subunit-targeted IL-23 inhibitor, has shown high efficacy and a favorable safety profile in clinical trials of moderate-to-severe plaque psoriasis (PsO). However, real-world data on patient satisfaction with the guselkumab One-Press device, particularly in Portuguese clinical practice, are limited.
METHODS: This real-world, prospective, multicenter, nationwide study evaluated patient satisfaction with self-administration of guselkumab using the One-Press device over 52 weeks in adults with moderate-to-severe plaque PsO. A total of 101 patients from 10 dermatology centers were enrolled between September 2022 and November 2023. Patient satisfaction was assessed using the Self-Injection Assessment Questionnaire (SIAQ) at baseline and week 20. Using the SIAQ, patients rated the One-Press device's acceptability across six domains predose and postdose (feeling about injections, self-confidence, and satisfaction with self-injection; postdose only: self-image, pain and skin reactions during or after the injection, and ease of self-injection device use). Quality of life (Dermatology Life Quality Index [DLQI]), clinical effectiveness (Investigator Global Assessment [IGA]), and safety were evaluated through week 52.
RESULTS: Mean SIAQ PRE Module score increased significantly from 6.9 ± 1.8 at baseline to 8.3 ± 1.5 at week 20 (p < 0.001), indicating improved self-injection experience. Injection-related anxiety decreased from 63.4% to 48.9%. Mean DLQI score improved from 8.5 ± 6.9 at baseline to 1.5 ± 2.8 at week 20 and 1.1 ± 3.0 at week 52; 70.8% of patients achieved DLQI 0/1 by week 52. Despite nearly 90% having prior biologic or systemic therapy exposure, IGA 0/1 ("clear" or "almost clear") was achieved by 86.3% of patients at week 20 and 91.0% at week 52. A total of 198 adverse events (AEs) were reported in 62.4% of patients and were mainly mild, localized injection-site reactions. One serious AE was considered related to guselkumab.
CONCLUSIONS: In routine clinical practice in Portugal, guselkumab self-administered using the One-Press device demonstrated high patient satisfaction, substantial quality-of-life improvement, robust clinical effectiveness, and a favorable safety profile. These real-world findings support the usability and benefit-risk profile of self-administered guselkumab for patients with moderate-to-severe plaque PsO.
METHODS: This real-world, prospective, multicenter, nationwide study evaluated patient satisfaction with self-administration of guselkumab using the One-Press device over 52 weeks in adults with moderate-to-severe plaque PsO. A total of 101 patients from 10 dermatology centers were enrolled between September 2022 and November 2023. Patient satisfaction was assessed using the Self-Injection Assessment Questionnaire (SIAQ) at baseline and week 20. Using the SIAQ, patients rated the One-Press device's acceptability across six domains predose and postdose (feeling about injections, self-confidence, and satisfaction with self-injection; postdose only: self-image, pain and skin reactions during or after the injection, and ease of self-injection device use). Quality of life (Dermatology Life Quality Index [DLQI]), clinical effectiveness (Investigator Global Assessment [IGA]), and safety were evaluated through week 52.
RESULTS: Mean SIAQ PRE Module score increased significantly from 6.9 ± 1.8 at baseline to 8.3 ± 1.5 at week 20 (p < 0.001), indicating improved self-injection experience. Injection-related anxiety decreased from 63.4% to 48.9%. Mean DLQI score improved from 8.5 ± 6.9 at baseline to 1.5 ± 2.8 at week 20 and 1.1 ± 3.0 at week 52; 70.8% of patients achieved DLQI 0/1 by week 52. Despite nearly 90% having prior biologic or systemic therapy exposure, IGA 0/1 ("clear" or "almost clear") was achieved by 86.3% of patients at week 20 and 91.0% at week 52. A total of 198 adverse events (AEs) were reported in 62.4% of patients and were mainly mild, localized injection-site reactions. One serious AE was considered related to guselkumab.
CONCLUSIONS: In routine clinical practice in Portugal, guselkumab self-administered using the One-Press device demonstrated high patient satisfaction, substantial quality-of-life improvement, robust clinical effectiveness, and a favorable safety profile. These real-world findings support the usability and benefit-risk profile of self-administered guselkumab for patients with moderate-to-severe plaque PsO.